CIPLA LTD vs Fresenius Kabi Oncology Ltd
A side-by-side comparison of CIPLA LTD (CIPLA) and Fresenius Kabi Oncology Ltd (FKONCO) — valuation, profitability, growth, and financial health — to help you judge which is the stronger buy today.
On the numbers, CIPLA LTD leads CIPLA vs FKONCO on 10 of 14 metrics (1 tied). See the breakdown below — the right pick still depends on your goals (value vs growth, risk appetite).
Valuation
How expensive each stock is relative to its earnings and book value. Lower usually means cheaper.
Profitability
How efficiently each company turns capital and sales into profit. Higher is better.
Growth
Three-year compounded growth. Faster-growing businesses can justify a higher valuation.
Size & financial health
Scale and balance-sheet strength. Bigger revenue/profit and lower debt are generally safer.
- + ["Company is almost debt free.", "Company has been maintaining a healthy dividend payout of 25.7%"]
- − ["The company has delivered a poor sales growth of 8.01% over past five years.", "Promoter holding has decreased over last 3 years: -4.34%"]
- − ["Stock is trading at 5.15 times its book value", "The company has delivered a poor sales growth of 10.1% over past five years.", "Tax rate seems low", "Company has a low return on equity of 6.57% over last 3 years.", "Company might be capitalizing the interest cost"]
This comparison is for informational purposes only and is not investment advice. Please consult a SEBI-registered advisor before investing.